MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025)

MapLight Therapeutics (MPLT) reported Free Cash Flow of -$47.2 million for Q4 2025, down 118.6% on a YoY basis from $253.8 million in Q4 2024, and down 118.6% sequentially from -$21.6 million in Q4 2024.

MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Free Cash Flow data on file, last reported at -$47.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 118.6% year-over-year to -$47.2 million; the trailing twelve-month figure through Dec 2025 stood at -$68.8 million (changed N/A YoY), and the FY2025 full-year result was -$138.6 million, down 74.17% from the prior year.
  • Free Cash Flow retreated to -$47.2 million in Q4 2025, from -$21.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$21.6 million in Q4 2024 to a low of -$47.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -19.58 Mn
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -2.49 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 158.09 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.29 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 848.30 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -354.95 Mn
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - -47.21 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -47.21 Mn
Dec 31, 2025 -47.21 Mn
Dec 31, 2024 -21.59 Mn
Dec 31, 2024 -21.59 Mn